Overcoming the Challenges of Conducting Early Feasibility Studies of Medical Devices in the United States

被引:19
|
作者
Holmes, David R., Jr. [1 ]
Califf, Robert [2 ]
Farb, Andrew [2 ]
Abel, Dorothy [2 ]
Mack, Michael [3 ]
Jensen, Tamara Syrek [4 ]
Zuckerman, Bram [2 ]
Leon, Martin [5 ]
Shuren, Jeff [2 ]
机构
[1] Mayo Clin, Dept Cardiol, Rochester, MN USA
[2] Food & Drug Adm, Silver Spring, MD USA
[3] Baylor Scott & White Hlth, Plano, TX USA
[4] Ctr Medicare & Medicaid Serv, Baltimore, MD USA
[5] Columbia Univ, Med Ctr, Ctr Intervent Vasc Therapy, New York, NY USA
基金
美国国家卫生研究院;
关键词
equipment design; new device development strategies; research design; research ethics committees; United States Food and Drug Administration;
D O I
10.1016/j.jacc.2016.07.769
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Initial clinical studies of new medical technologies involve a complex balance of research participant benefits versus risks and costs of uncertainty when novel concepts are tested. The Food and Drug Administration Center for Devices and Radiological Health has recently introduced the Early Feasibility Study (EFS) Program for facilitating the conduct of these studies under the Investigational Device Exemption regulations. However, a systematic approach is needed to successfully implement this program while affording appropriate preservation of the rights and interests of patients. For this to succeed, a holistic reform of the clinical studies ecosystem for performing early-stage clinical research in the United States is necessary. The authors review the current landscape of the U.S. EFS and make recommendations for developing an efficient EFS process to meet the goal of improving access to early-stage, potentially beneficial medical devices in the United States. (C) 2016 by the American College of Cardiology Foundation. All rights reserved.
引用
收藏
页码:1908 / 1915
页数:8
相关论文
共 50 条